Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

NCT04143711 is registered in ClinicalTrials.gov with Dragonfly Therapeutics as lead sponsor.

NCT NCT04143711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04143711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Lead sponsor
Dragonfly Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
November 11, 2019
Completion date
December 5, 2025
Enrollment
270 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult